Nowarta Biopharma

Executive Summary

Nowarta Biopharma is a clinical-stage biotechnology company developing botanical therapeutics for viral infections, with its lead candidate Nowarta110 positioned as a potential first-in-class topical treatment for plantar warts caused by HPV. Currently in Phase 3 trials, Nowarta110 leverages a novel botanical mechanism that may offer efficacy advantages over existing cryotherapy and salicylic acid treatments. The company is also expanding its pipeline to address cervical HPV infections, COVID-19, and certain cancers, highlighting the broad antiviral potential of its platform. While still private and pre-revenue, Nowarta's focus on an underserved dermatology indication with high unmet need provides a clear path to market, though execution risks remain given early-stage data and regulatory hurdles.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 top-line results for Nowarta110 in plantar warts60% success
• Q1 2027Initiation of Phase 2 trial for cervical HPV infections40% success
• Q2 2026Preclinical proof-of-concept data for COVID-19 program30% success